Amarin (AMRN) Vascepa Exclusivity Status Not in FDA Orange Book March Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
May 17, 2013 2:32 PM EDTAmarin (Nasdaq: AMRN) is rebounding following an earlier dip on news that its Vascepa wasn't in the FDA Orange Book for April.
To go to the FDA's Orange Book website, click here.
Shares are down 0.5 percent Friday.... More
